US Patent 9,931,305: Claim Scope, Patent Expiration, Orange Book Status and Competitive Landscape

US Patent 9,931,305 covers continuously cast, self-supporting oral films containing finely particulate active ingredients distributed with sufficient uniformity to produce individual doses. The patent focuses on three technical controls: a water-soluble or water-swellable polymer matrix, viscosity that prevents particle aggregation or settling, and dose-to-dose active-content variation of no more than 10%, or 5% under narrower claims.

The patent is a platform patent rather than an API-specific patent. Its commercial relevance is highest for oral mucosal films, including sublingual and buccal products containing controlled substances, analgesics, tadalafil, apomorphine, alprazolam and other small-molecule drugs. The patent family is associated with MonoSol Rx, now associated with Aquestive Therapeutics, and the technology has been licensed or used in products marketed by third parties, including Indivior's Suboxone sublingual film platform.

What does US Patent 9,931,305 cover?

US 9,931,305 covers drug-delivery compositions and oral films manufactured by continuous casting. The patent claims both the formulation and structural characteristics of the film.

Claim group	Subject matter	Principal limitations
Claims 1-11	Drug-delivery composition	Self-supporting continuously cast film, uniformly distributed active, water-soluble or water-swellable polymer matrix, taste masking, active particle size of 200 microns or less
Claims 12-19	Multilayer oral film	First and additional polymer layers, continuous casting of at least one layer, mucosal delivery, uniform dosage, taste masking or controlled release
Claims 20-25	Restricted-active multilayer film	Opiates, analgesics, tadalafil, apomorphine, hormones, alprazolam and specified related categories
Claims 26-30	Manufacturing-line composition	Continuous manufacturing-line casting, particulate active, viscosity-controlled uniformity and taste masking
Claims 31-34	Residual-solvent limitation	Less than about 10% of specified solvents in the unit dose

The independent claims are composition and product claims. They do not expressly claim a step-by-step manufacturing process in the conventional method-of-manufacturing format. Claim 26 comes closest to a process-linked limitation by requiring a film produced on a manufacturing line and a matrix capable of continuous casting without loss of substantial uniformity.

How should the independent claims be construed?

Claim 1: continuously cast film composition

Claim 1 requires all of the following elements:

A self-supporting, continuously cast film.
At least one active substantially uniformly stationed in the film.
A flowable water-soluble or water-swellable film-forming matrix.
A polymer selected from the listed polymer classes.
Matrix viscosity sufficient to maintain non-self-aggregating uniformity.
Active particle size of 200 microns or less.
A taste-masking agent comprising a flavor, sweetener or flavor enhancer.
Unit doses cut from the film with no more than 10% variation from the desired active amount.

The claim is broad because it does not limit the active to a particular drug, dose, film thickness, casting speed or release profile. It is narrower than a general oral-film claim because every limitation must be met, including particle size, taste masking, continuous casting and the quantitative uniformity requirement.

Claim 12: multilayer oral mucosal film

Claim 12 covers a film with:

A first polymer layer;
One or more additional polymer layers;
At least one layer containing the active;
Active particles no larger than 200 microns;
A viscosity-controlled matrix;
Substantially uniform active distribution;
At least one continuously cast layer;
A taste-masking agent, controlled-release agent or both; and
Unit-dose variation of no more than 10%.

The claim does not require every layer to contain an active. Claims 10 and 11 confirm that a multilayer film can include an inactive layer. This creates coverage for barrier layers, backing layers, taste-masking layers and drug-containing layers positioned for direct mucosal contact.

Claim 20: multilayer film for specified active categories

Claim 20 is materially narrower than claim 12 because it restricts the active to a defined group, including opiates, opiate derivatives, analgesics, tadalafil, apomorphine, migraine treatments, hormones and alprazolam.

It retains the core limitations of:

Continuous casting;
A self-supporting individual dose;
Particle size of 200 microns or less;
Viscosity sufficient to lock the active into the matrix;
Substantially uniform distribution; and
Unit-dose variation of no more than 10%.

For opioid-film products, claim 20 is commercially more targeted than claim 1 because it expressly identifies opiates and opiate derivatives. A product containing an opioid could potentially fall within claims 1, 12, 20 and 26 simultaneously, depending on its formulation and manufacturing process.

Claim 26: manufacturing-line and particulate-active coverage

Claim 26 adds a manufacturing-line requirement. It covers a continuously cast film produced on a line using a flowable polymer matrix that maintains active uniformity during casting and drying.

Claims 27-30 narrow the claim by requiring:

Active particle size of 100 microns or less;
Post-casting and post-drying uniformity of no more than 5%;
Taste-masking agent at 0.01% to 10% by weight; or
An opiate or opiate derivative as the active.

Claim 26 is important because it addresses a principal scale-up problem in film manufacturing: particle settling, agglomeration or migration during continuous coating, drying and converting.

What technical features create infringement risk?

A competing film is at greatest literal-infringement risk when it has the following profile:

Risk factor	Patent limitation
Manufacturing	Continuous casting on a production line
Dosage form	Self-supporting oral or mucosal film
Polymer	Water-soluble or water-swellable polymer from the listed classes
Active	Particulate active with a size of 200 microns or less
Rheology	Viscosity that prevents aggregation or nonuniform stationing
Dose control	Cut units varying by no more than 10%, or 5% under dependent claims
Organoleptic control	Flavor, sweetener, flavor enhancer or anesthetic
Architecture	Multilayer film, including an active-contact layer
Product chemistry	Ion-exchange resin, controlled-release agent or coated active

The most difficult limitation to assess is "viscosity sufficient to aid in substantially maintaining non-self-aggregating uniformity." This is functional language. In litigation, the analysis would likely focus on formulation viscosity, solids content, particle-density differences, rheology data, mixing conditions and manufacturing records.

"Substantially uniformly distributed" and "substantially equally sized individual unit doses" are also fact-intensive limitations. Analytical testing would normally include assay results from units sampled across the web, across the width of the film and at different points in the production run.

How broad are the polymer claims?

Claims 1, 12, 20 and 26 identify extensive polymer classes, including:

Cellulose and cellulose derivatives;
Polyethylene oxide;
Pullulan;
HPMC, HEC and hydroxypropyl cellulose;
Polyvinyl pyrrolidone;
Carboxymethyl cellulose;
Polyvinyl alcohol;
Sodium alginate;
Xanthan, guar, acacia and arabic gums;
Polyacrylic acid;
Starch;
Gelatin; and
Combinations of these materials.

Claims 3, 4 and 16 target polyethylene oxide molecular-weight ranges. Claim 3 covers 100,000 to 900,000 molecular weight. Claim 4 divides the range into 100,000 to 300,000 and 600,000 to 900,000, including combinations.

The polymer definition is broad but closed-ended. A formulation using a polymer outside the listed classes may have a stronger non-infringement position under the literal claim language, although the doctrine of equivalents could remain relevant depending on the polymer's function and prosecution history.

What uniformity thresholds does the patent require?

The patent uses two principal assay thresholds:

Claim limitation	Required unit-dose uniformity
Claims 1, 12, 20 and 26	No more than 10% variation from the desired active amount
Claim 6	No more than 5% variation
Claim 28	No more than 5% after casting and drying
Claim 27	Active particle size of 100 microns or less

The claims do not define a single analytical protocol. The specification and prosecution history would be important in determining whether "do not vary by more than 10%" means deviation from target strength, relative standard deviation, individual assay acceptance criteria or another measurement.

For freedom-to-operate purposes, testing should compare the accused product against the claimed threshold under reproducible sampling conditions. A manufacturer should not assume that manufacturing variability above the threshold avoids infringement if routine batches normally meet the claimed uniformity requirement.

What products and active ingredients could fall within the claims?

The Markush groups are unusually extensive. They identify broad therapeutic categories, including:

Central nervous system drugs;
Opioids and opioid derivatives;
Analgesics;
Anticonvulsants;
Antidepressants;
Antipsychotics;
Cardiovascular agents;
Antihistamines;
Anti-infectives;
Hormones;
Migraine drugs;
Erectile-dysfunction therapies;
Gastrointestinal agents;
Respiratory drugs;
Anti-obesity agents;
Anticoagulants;
Anti-emetics; and
Genetic-modifying and biologic-response agents.

Claim 9 specifically includes tadalafil, apomorphine, alprazolam, opiates, opiate derivatives and analgesics. Claims 14 and 20 repeat or narrow several of these categories.

The claims do not require a particular branded product. A generic or follow-on manufacturer could face risk even if the active ingredient is not named, provided the product satisfies the structural, formulation and manufacturing limitations.

What is the Orange Book status of US 9,931,305?

US 9,931,305 has been associated with oral-film products and is commercially relevant to sublingual-film products, particularly products using MonoSol's film technology. The Orange Book question is product-specific: FDA listings attach patents to an approved drug application, not to every product that could technically practice the patent.

For a Suboxone-related analysis, the relevant issues are:

Whether US 9,931,305 is listed against the relevant NDA and dosage form;
Whether the listing covers the sublingual film rather than the active ingredient generally;
Whether FDA has recorded a pediatric exclusivity extension;
Whether the patent is still unexpired in the current Orange Book data; and
Whether an ANDA applicant has submitted a Paragraph IV certification.

FDA's Orange Book identifies patents and exclusivity associated with approved drug products. It does not resolve claim construction or infringement. Patent status must be read together with USPTO Patent Center, the patent's maintenance-fee record and any terminal disclaimer or patent-term-adjustment calculation (FDA, 2024; USPTO, 2024a).

When does US Patent 9,931,305 lose exclusivity?

The patent issued on April 3, 2018. Its effective term depends on the earliest nonprovisional filing date in the continuation chain, any patent-term adjustment, terminal disclaimer and any applicable pediatric extension.

The family originated from early-2000s oral-film filings. On that basis, the ordinary 20-year term would generally point to an expiration date in the mid-2020s, subject to USPTO adjustments. Public commercial records have associated related MonoSol film patents with expiration around 2027 because of patent-term adjustment and related term calculations.

The legally operative date is the USPTO-calculated expiration date, not the issue date and not the date printed in a commercial patent database. If the patent is listed in the Orange Book, an ANDA applicant may still face a statutory stay or litigation risk before the patent expires, depending on the timing and content of the Paragraph IV notice.

What Paragraph IV challenges and litigation affect the patent?

A Paragraph IV certification is available when an ANDA applicant asserts that a listed patent is invalid, unenforceable or will not be infringed. For a film product, the most likely challenges would target:

Anticipation by earlier oral-film or solvent-casting disclosures.
Obviousness based on combining known film-forming polymers, taste masking and particle-size control.
Lack of written description for the extensive therapeutic Markush groups.
Lack of enablement across the full range of polymers, drugs and dosage forms.
Indefiniteness of "substantially uniformly," "substantially equally sized" and "viscosity sufficient."
Non-infringement based on batch casting, extrusion, lamination or a non-listed polymer.
Failure to satisfy the continuous-casting limitation.

A product-specific litigation search should include the patent number, the relevant NDA, ANDA numbers and the patent owner or exclusive licensee. Patent litigation involving related MonoSol oral-film patents is commercially relevant because courts may construe overlapping terms such as "self-supporting film," "uniformity," "continuously cast" and "film-forming matrix."

No conclusion about a live case, settlement or current Paragraph IV notice should be drawn solely from the patent claims. Such conclusions require the current PACER docket, FDA Paragraph IV records and Orange Book listing history.

What settlement agreements and licensing deals matter?

The principal commercial structure around this technology has involved MonoSol's oral-film platform and licensing or commercialization arrangements with product companies. Indivior's Suboxone sublingual film is the most visible commercial example of a product using MonoSol film technology.

A license does not eliminate product-level patent risk. The agreement may cover only specified products, territories, APIs, manufacturing sites or fields of use. Key diligence points include:

Whether the license covers US Patent 9,931,305 specifically;
Whether the license is exclusive or nonexclusive;
Royalty rates and minimum payments;
Sublicensing rights;
Patent-prosecution control;
Enforcement rights;
Post-expiration know-how obligations;
Manufacturing-site restrictions; and
Settlement terms governing generic entry.

Public filings from the licensor, licensee and SEC reporting companies should be reviewed for current royalty and litigation arrangements (Indivior PLC, 2024; Aquestive Therapeutics, 2024).

How strong is the patent estate?

The estate is strongest against a manufacturer that reproduces the complete platform:

Continuous web casting;
Fine-particle API;
Viscosity-controlled suspension;
Self-supporting film;
Taste-masking formulation; and
Dose units cut from a uniform web.

The estate is weaker where a competitor uses a materially different process or dosage form. Potential design-around routes include:

Design-around route	Potential effect
Batch casting rather than continuous casting	May avoid a central limitation of claims 1, 12, 20 and 26
Extrusion, compression or spray-drying	May avoid continuous-casting limitations
Polymer outside the listed classes	May avoid literal polymer limitation
Active particle size above 200 microns	May avoid literal particle-size limitation
Non-self-supporting strip or carrier-backed system	May avoid self-supporting-film limitation
No flavor, sweetener or flavor enhancer	May avoid claims requiring taste masking
Unit doses not cut from a continuous web	May avoid the claimed dosage-unit architecture
Active dissolved rather than particulate	May create a non-infringement argument, depending on claim construction

These routes can affect product performance, regulatory comparability and manufacturing economics. A design-around that avoids the patent may create new risks under other MonoSol, Aquestive, Indivior or API-specific patents.

How does this patent compare with API and formulation patents?

US 9,931,305 is a delivery-platform patent. It differs from:

API composition-of-matter patents, which typically provide the strongest exclusivity but expire earlier or are absent for older drugs;
Salt, polymorph and crystal-form patents, which protect the active ingredient's solid state;
Method-of-use patents, which protect treatment of a defined disease or patient population;
Drug-specific formulation patents, which protect a particular film composition, release profile or combination; and
Manufacturing patents, which protect casting, drying, converting or packaging operations.

For a generic sublingual film, the relevant risk is cumulative. A generic applicant may avoid one platform patent yet remain exposed to a separate drug-specific formulation patent, method-of-use patent or manufacturing patent.

Is there biosimilar risk?

There is no conventional biosimilar pathway for US Patent 9,931,305. The claims concern small-molecule oral films and manufacturing technology, not a biologic reference product. A product containing a biologic or peptide could raise separate biologic-manufacturing and formulation questions, but the patent itself does not create a biosimilar exclusivity period under the Public Health Service Act.

For small-molecule products, the principal regulatory pathway is an ANDA under the Federal Food, Drug, and Cosmetic Act. A 505(b)(2) applicant could also face the patent if it relies on some of the reference product's safety or efficacy findings while using a new film formulation (FDA, 2023).

What generic launch scenarios exist?

Launch after patent expiry

This is the lowest litigation-risk path if no other listed patent or regulatory exclusivity remains. The applicant must still satisfy bioequivalence, product quality, abuse-deterrence requirements where applicable and manufacturing controls.

Paragraph IV launch

An ANDA applicant can challenge the patent before expiry. The patent owner may sue within 45 days after receiving a proper notice, potentially triggering a 30-month stay of approval under Section 505(j)(5)(B)(iii).

Section VIII carve-out

A carve-out may be available for a patented method of use, but it is less useful for a platform patent claiming the film composition itself. A composition or dosage-form patent generally cannot be removed through a simple method-of-use labeling carve-out.

At-risk launch

An applicant may launch before final resolution of the patent dispute. This exposes the applicant to damages, an injunction request and possible market withdrawal. The commercial decision depends on the remaining patent term, expected launch value, litigation probability and availability of alternative film technology.

What geographic coverage does the patent provide?

US Patent 9,931,305 provides rights only in the United States. Parallel protection may exist in Canada, Europe, Australia and other jurisdictions through related national applications, but foreign claims, expiration dates and enforceability must be analyzed independently.

A US license does not automatically grant rights to manufacture abroad for US importation. Conversely, a foreign patent may restrict manufacture in another country even if the US patent has expired. Global launch planning should map:

US composition and process claims;
European national validations;
Canadian and Australian equivalents;
Manufacturing-country patents;
Importation exposure;
Regulatory exclusivity by market; and
Patent term and supplementary protection certificates.

What manufacturing and intellectual-property barriers remain after expiry?

Patent expiry does not remove all barriers to market entry. Oral-film manufacturers may still need:

Validated continuous-casting equipment;
Uniform suspension and rheology controls;
Particle-size and agglomeration controls;
Drying and residual-solvent validation;
Film-cutting and web-registration equipment;
Content-uniformity testing;
Taste-masking development;
Controlled-substance security systems;
FDA-compliant manufacturing sites; and
Freedom to operate under later patents.

The strongest practical barrier may be manufacturing know-how rather than the expired or expiring claims. Continuous casting at commercial scale requires stable feed viscosity, controlled drying, web handling and reliable dose conversion.

Key Takeaways

US 9,931,305 is a broad oral-film platform patent focused on continuous casting and active-content uniformity.
The core claim combination is a self-supporting film, listed water-soluble or water-swellable polymer, active particles no larger than 200 microns, viscosity-controlled suspension, taste masking and unit-dose variation of no more than 10%.
Claims 20 and 30 create targeted exposure for opioid and other specified active-containing films.
Claims 27 and 28 impose narrower 100-micron and 5% uniformity requirements.
The patent is more vulnerable to design-around through non-continuous manufacturing, alternative polymers, non-particulate actives or non-film dosage forms than through minor formulation changes.
The patent's operative expiration date depends on the USPTO term calculation, including patent-term adjustment, terminal disclaimer and any pediatric extension.
Orange Book relevance is NDA-specific. A listing does not by itself establish infringement or validity.
Biosimilar rules generally do not apply because the claims cover small-molecule oral-film delivery technology.
Generic applicants should analyze this patent with API, formulation, method-of-use, manufacturing and controlled-substance patents as a single portfolio.

FAQs About US Patent 9,931,305

Does US 9,931,305 claim Suboxone specifically?

No. The claims are platform claims and do not require buprenorphine or naloxone. Its relevance to Suboxone depends on the product's formulation, film architecture and manufacturing process.

Can a generic avoid US 9,931,305 by using a different film polymer?

Potentially. The independent claims identify specified polymer classes. A polymer outside those classes may support a literal non-infringement position, but the entire claim must be analyzed and the doctrine of equivalents may remain relevant.

Does a 5% assay result automatically infringe the patent?

No. A 5% result is relevant only if the product also satisfies the other limitations of the applicable claim, including continuous casting, particle size, polymer matrix and taste-masking requirements.

Is a 505(b)(2) product exposed to this patent?

Yes, potentially. A 505(b)(2) applicant using a film dosage form or relying on a listed reference product may face the patent even if it is not pursuing a conventional ANDA.

Are manufacturing records important in an infringement case?

Yes. Mixing viscosity, particle-size distribution, web-casting records, drying conditions, assay mapping and unit-dose cutting data can determine whether the product meets the functional and quantitative limitations.

References

Aquestive Therapeutics, Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
Food and Drug Administration. (2023). ANDA submissions: Content and format of an ANDA. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services.
Indivior PLC. (2024). Annual report and accounts. U.S. Securities and Exchange Commission.
U.S. Patent and Trademark Office. (2018). U.S. Patent No. 9,931,305, Uniformity of dosage units in a film. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (2024a). Patent Center: Patent term adjustment and prosecution history records. U.S. Department of Commerce.
U.S. Patent and Trademark Office. (2024b). Manual of Patent Examining Procedure, Chapter 2700: Patent terms and adjustments. U.S. Department of Commerce.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077803	⤷ Start Trial
Austria	536868	⤷ Start Trial
Austria	536869	⤷ Start Trial
Austria	553746	⤷ Start Trial
Australia	2002332118	⤷ Start Trial
Australia	2002348432	⤷ Start Trial
Australia	2002362772	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,931,305

Summary for Patent: 9,931,305